Anika Therapeutics Management
Management criteria checks 3/4
Anika Therapeutics' CEO is Steve Griffin, appointed in Jun 2024, has a tenure of 2.17 years. total yearly compensation is $2.03M, comprised of 24.6% salary and 75.4% bonuses, including company stock and options. directly owns 0.34% of the company’s shares, worth $953.25K. The average tenure of the management team and the board of directors is 1.8 years and 4.8 years respectively.
Key information
Steve Griffin
Chief executive officer
US$2.0m
Total compensation
| CEO salary percentage | 24.59% |
| CEO tenure | 2.2yrs |
| CEO ownership | 0.3% |
| Management average tenure | 1.8yrs |
| Board average tenure | 4.8yrs |
Recent management updates
Recent updates
ANIK: Q2 Beat And Guidance Raise Will Test Profitability Durability
Analysts lifted their price targets on Anika Therapeutics to $21, highlighting a recent Q2 beat, stronger margins, raised guidance, and an updated view of more durable profitability supported by OEM and international growth, along with structural cost improvements. Analyst Commentary Recent research on Anika Therapeutics points to a more constructive view on the stock following the Q2 results, with analysts updating their models to reflect the new price targets and revised outlook.Bullish On Anika Therapeutics's Pullback As Integrity Scales
Summary Anika Therapeutics is refocusing on HA-based OA pain management and regenerative orthopedic products. The main drivers here are Monovisc, Orthovisc, and Integrity. Particularly, ANIK’s Integrity received 510(k) clearance in 2023. Recently, its revenues have more than doubled in 2025. Hyalofast and Cingal also offer interesting regulatory catalysts, but they bring FDA timing and approval risks. ANIK’s valuation seems quite cheap overall, with no financial debt and positive TTM cash flows. So, despite its inherent regulatory and execution risks, I remain bullish. Read the full article on Seeking AlphaRevenues Working Against Anika Therapeutics, Inc.'s (NASDAQ:ANIK) Share Price Following 26% Dive
NasdaqGS:ANIK 1 Year Share Price vs Fair Value Explore Anika Therapeutics's Fair Values from the Community and select...Revenues Working Against Anika Therapeutics, Inc.'s (NASDAQ:ANIK) Share Price
Anika Therapeutics, Inc.'s ( NASDAQ:ANIK ) price-to-sales (or "P/S") ratio of 1.4x might make it look like a strong buy...Improved Revenues Required Before Anika Therapeutics, Inc. (NASDAQ:ANIK) Shares Find Their Feet
With a price-to-sales (or "P/S") ratio of 1.4x Anika Therapeutics, Inc. ( NASDAQ:ANIK ) may be sending very bullish...Is There An Opportunity With Anika Therapeutics, Inc.'s (NASDAQ:ANIK) 44% Undervaluation?
Key Insights Anika Therapeutics' estimated fair value is US$44.70 based on 2 Stage Free Cash Flow to Equity Anika...Companies Like Anika Therapeutics (NASDAQ:ANIK) Can Afford To Invest In Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Anika Therapeutics: New Share Price Low May Imply New Upside Opportunity
Anika Therapeutics' share price is being punished by the market owing to some possibly over-ambitious growth projections made in June last year. Management believed it could nearly double revenues, to $230m, by 2024, but after a so-so 2021, these plans have been abandoned. Anika is attempting to pivot from pain management and its Monovisc and Orthovisc injectables, to joint preservation, having acquired two businesses in 2020. Progress has not been bad - Anika is growing revenues, is profitable, and has nearly $100m cash - but it hasn't been as good as promised. I'm not entirely sure about Anika's long-term prospects, since it's moving away from its core revenues generating business into a new field, but I do think the market undervalues the business at current market cap of ~$350m.CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | -US$3m |
| Mar 31 2026 | n/a | n/a | -US$11m |
| Dec 31 2025 | US$2m | US$500k | -US$10m |
| Sep 30 2025 | n/a | n/a | -US$14m |
| Jun 30 2025 | n/a | n/a | -US$13m |
| Mar 31 2025 | n/a | n/a | -US$11m |
| Dec 31 2024 | US$3m | US$279k | -US$9m |
Compensation vs Market: Steve's total compensation ($USD2.03M) is about average for companies of similar size in the US market ($USD1.63M).
Compensation vs Earnings: Steve's compensation has been consistent with company performance over the past year.
CEO
Steve Griffin (40 yo)
Mr. Stephen D. Griffin, also known as Steve, is President, Chief Executive Officer and Director of Anika Therapeutics, Inc. since February 01, 2026 and serves as its Principal Financial Officer. He was Exe...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chair | 8yrs | US$4.89m | 2.02% $ 5.6m | |
| President | 2.2yrs | US$2.03m | 0.34% $ 953.3k | |
| Senior VP | 5.1yrs | US$765.54k | 0.18% $ 499.9k | |
| Executive Director of Corporate Development & Investor Relations | no data | no data | no data | |
| VP & Chief Human Resources Officer | 4.5yrs | no data | no data | |
| Senior Vice President of Commercial | less than a year | no data | no data | |
| Senior Vice President of Regulatory | 1.4yrs | no data | no data |
Experienced Management: ANIK's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chair | 8yrs | US$4.89m | 2.02% $ 5.6m | |
| President | less than a year | US$2.03m | 0.34% $ 953.3k | |
| Lead Independent Director | 7yrs | US$267.50k | 0.41% $ 1.1m | |
| Independent Director | 4.8yrs | US$225.00k | 0.32% $ 882.7k | |
| Independent Director | 2.3yrs | US$222.50k | 0.15% $ 423.0k | |
| Independent Director | 3.3yrs | US$212.50k | 0.31% $ 862.8k | |
| Independent Director | 5.9yrs | US$230.00k | 0.36% $ 992.6k |
Experienced Board: ANIK's board of directors are considered experienced (4.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/04 03:25 |
| End of Day Share Price | 2026/08/03 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Anika Therapeutics, Inc. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Petusky | Barrington Research Associates, Inc. |
| Anderson Schock | B. Riley Securities, Inc. |
| Mark Landy | Northland Capital Markets |